Epithelioid hemangioma (EH) is an uncommon benign vascular lesion usually present as subcutaneous nodules in the head and neck area. Sometimes, these lesions can occur in the peripheral arteries, and when they do, they can be mistaken for aneurysmal dilatations of that respective vessel. We report a case of a 43-year-old male who underwent surgical recession of a radial aneurysm, which after anatomopathological examination, revealed an EH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.48729/pjctvs.236 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Skin Biopsy Targeting Senile Hemangiomas for the Diagnosis of Intravascular Large B-cell Lymphoma.
Cureus
December 2024
Internal Medicine, Saitama Citizens Medical Center, Saitama, JPN.
Intravascular large B-cell lymphoma (IVLBCL) is characterized by clinical presentations described as B symptoms, consisting of fever, night sweats, and weight loss. Intravascular lymphomas are more frequently diagnosed in elderly patients and are challenging to diagnose because of their nonspecific clinical presentation. Malignant lymphomas are recognized as the leading cause of fever of unknown origin.
View Article and Find Full Text PDFBMP4 regulates differentiation of nestin-positive stem cells into melanocytes.
Cell Mol Life Sci
January 2025
Department of Anesthesiology, Shenzhen Children's Hospital, Yitian Road 7019, Shenzhen, 518000, China.
Hair follicle (HF) development and pigmentation are complex processes governed by various signaling pathways, such as TGF-β and FGF signaling pathways. Nestin + (neural crest like) stem cells are also expressed in HF stem cells, particularly in the bulge and dermal papilla region. However, the specific role and differentiation potential of these Nestin-positive cells within the HF remain unclear, especially regarding their contribution to melanocyte formation and hair pigmentation.
View Article and Find Full Text PDFEvaluation of Predictive Factors for Transarterial Bleomycin-Lipiodol Embolization Success in Treating Giant Hepatic Hemangiomas.
Cancers (Basel)
December 2024
Department of General, Interventional and Neuroradiology, Wroclaw Medical University, 50-367 Wrocław, Poland.
Giant hepatic hemangiomas are challenging to manage, requiring effective therapeutic approaches. Transarterial bleomycin-lipiodol embolization (TACE) has shown promise as a treatment option, yet predictive factors for its success are not well defined. This study aimed to assess the efficacy of TACE for giant hepatic hemangiomas and identify factors influencing treatment outcomes.
View Article and Find Full Text PDFPrimary intrarenal hemangioma - A series of 39 cases.
Ann Diagn Pathol
January 2025
Department of Pathology and Laboratory Medicine, Brigham and Women's Hospital, Boston, USA. Electronic address:
Intrarenal hemangiomas lack concise clinicopathologic information, due to the predominance of single case reports and inclusion of other vascular neoplasms and hemangiomas of perirenal, hilar, and renal vein origin. Herein, in this multi-institutional study we evaluate clinicopathologic features of 39 intrarenal hemangiomas. The median age was 62 years (range = 27-94 years; 2:1 male to female ratio), with left-sided predominance (left = 21, right = 13; one case was bilateral).
View Article and Find Full Text PDFBenign eyelid lesions and its histopathological picture: A case-series.
J Family Med Prim Care
December 2024
Department of Ophthalmology, AL-Falah Medical College, Faridabad, Haryana, India.
Our prospective case series evaluates the clinical feature, histopathological picture, and treatment of benign eyelid lesions in a tertiary referral setting. Participants were first nine patients referred to the author with unilateral eyelid swelling. Main outcome measures were clinical features, histopathological picture, and response to surgical intervention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!